BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 36383906)

  • 1. Antibody-Drug Conjugates in Breast Cancer: What Is Beyond HER2?
    Nicolò E; Repetto M; Boscolo Bielo L; Tarantino P; Curigliano G
    Cancer J; 2022 Nov-Dec 01; 28(6):436-445. PubMed ID: 36383906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
    Ferraro E; Drago JZ; Modi S
    Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Next-generation antibody-drug conjugates for breast cancer: Moving beyond HER2 and TROP2.
    Schlam I; Moges R; Morganti S; Tolaney SM; Tarantino P
    Crit Rev Oncol Hematol; 2023 Oct; 190():104090. PubMed ID: 37562695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-drug conjugates in breast cancer: the chemotherapy of the future?
    Nicolò E; Zagami P; Curigliano G
    Curr Opin Oncol; 2020 Sep; 32(5):494-502. PubMed ID: 32657795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future Roles.
    Fenton MA; Tarantino P; Graff SL
    Curr Oncol; 2023 Nov; 30(12):10211-10223. PubMed ID: 38132377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breaking barriers in triple negative breast cancer (TNBC) - Unleashing the power of antibody-drug conjugates (ADCs).
    Dri A; Arpino G; Bianchini G; Curigliano G; Danesi R; De Laurentiis M; Del Mastro L; Fabi A; Generali D; Gennari A; Guarneri V; Santini D; Simoncini E; Zamagni C; Puglisi F
    Cancer Treat Rev; 2024 Feb; 123():102672. PubMed ID: 38118302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-drug conjugates transform the outcome of individuals with low-HER2-expression advanced breast cancer.
    Qu F; Lu R; Liu Q; Wu X; Huang X; Yin Y; Li W
    Cancer; 2024 Apr; 130(S8):1392-1402. PubMed ID: 38271367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-Drug Conjugates in Breast Cancer: Ascent to Destiny and Beyond-A 2023 Review.
    Xiao T; Ali S; Mata DGMM; Lohmann AE; Blanchette PS
    Curr Oncol; 2023 Jul; 30(7):6447-6461. PubMed ID: 37504334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody drug conjugates targeting HER2: Clinical development in metastatic breast cancer.
    Rassy E; Rached L; Pistilli B
    Breast; 2022 Dec; 66():217-226. PubMed ID: 36334569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-Drug Conjugates in Breast Cancer: Spotlight on HER2.
    Abelman RO; Medford A; Spring L; Bardia A
    Cancer J; 2022 Nov-Dec 01; 28(6):423-428. PubMed ID: 36383904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementation of antibody-drug conjugates in HER2-positive solid cancers: Recent advances and future directions.
    Yu J; Li M; Liu X; Wu S; Li R; Jiang Y; Zheng J; Li Z; Xin K; Xu Z; Li S; Chen X
    Biomed Pharmacother; 2024 May; 174():116522. PubMed ID: 38565055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical perspective: Antibody-drug conjugates for the treatment of HER2-positive breast cancer.
    Najminejad Z; Dehghani F; Mirzaei Y; Mer AH; Saghi SA; Abdolvahab MH; Bagheri N; Meyfour A; Jafari A; Jahandideh S; Gharibi T; Amirkhani Z; Delam H; Mashatan N; Shahsavarani H; Abdollahpour-Alitappeh M
    Mol Ther; 2023 Jul; 31(7):1874-1903. PubMed ID: 36950736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and biological assessment of MMAE-trastuzumab antibody-drug conjugates (ADCs).
    Yaghoubi S; Gharibi T; Karimi MH; Sadeqi Nezhad M; Seifalian A; Tavakkol R; Bagheri N; Dezhkam A; Abdollahpour-Alitappeh M
    Breast Cancer; 2021 Jan; 28(1):216-225. PubMed ID: 32889587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unveiling the antibody-drug conjugates portfolio in battling Triple-negative breast cancer: Therapeutic trends and Future horizon.
    Khadela A; Soni S; Shah AC; Pandya AJ; Megha K; Kothari N; Cb A
    Med Oncol; 2022 Dec; 40(1):25. PubMed ID: 36456774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bispecific Antibodies and Antibody-Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs.
    Andreev J; Thambi N; Perez Bay AE; Delfino F; Martin J; Kelly MP; Kirshner JR; Rafique A; Kunz A; Nittoli T; MacDonald D; Daly C; Olson W; Thurston G
    Mol Cancer Ther; 2017 Apr; 16(4):681-693. PubMed ID: 28108597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Future potential targets of antibody-drug conjugates in breast cancer.
    Corti C; Boscolo Bielo L; Schianca AC; Salimbeni BT; Criscitiello C; Curigliano G
    Breast; 2023 Jun; 69():312-322. PubMed ID: 36996620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy.
    Goldenberg DM; Sharkey RM
    Expert Opin Biol Ther; 2020 Aug; 20(8):871-885. PubMed ID: 32301634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
    Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D
    Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody-Drug Conjugates in Breast Cancer.
    Duro-Sánchez S; Nadal-Serrano M; Lalinde-Gutiérrez M; Arenas EJ; Bernadó Morales C; Morancho B; Escorihuela M; Pérez-Ramos S; Escrivá-de-Romaní S; Gandullo-Sánchez L; Pandiella A; Esteve-Codina A; Rodilla V; Dijcks FA; Dokter WHA; Cortés J; Saura C; Arribas J
    Cancer Res; 2022 Dec; 82(24):4670-4679. PubMed ID: 36222720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates.
    Jackson D; Atkinson J; Guevara CI; Zhang C; Kery V; Moon SJ; Virata C; Yang P; Lowe C; Pinkstaff J; Cho H; Knudsen N; Manibusan A; Tian F; Sun Y; Lu Y; Sellers A; Jia XC; Joseph I; Anand B; Morrison K; Pereira DS; Stover D
    PLoS One; 2014; 9(1):e83865. PubMed ID: 24454709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.